Details

Autor(en) / Beteiligte

• Abderrahmani, Amar
• Yengo, Loïc
• Caiazzo, Robert
• Canouil, Mickaël
• Cauchi, Stéphane
• Raverdy, Violeta
• Plaisance, Valérie
• Pawlowski, Valérie
• Lobbens, Stéphane
• Maillet, Julie
• Rolland, Laure
• Boutry, Raphael
• Queniat, Gurvan
• Kwapich, Maxime
• Tenenbaum, Mathie
• Bricambert, Julien
• Saussenthaler, Sophie
• Anthony, Elodie
• Jha, Pooja
• Derop, Julien
• Sand, Olivier
• Rabearivelo, Iandry
• Leloire, Audrey
• Pigeyre, Marie
• Daujat-Chavanieu, Martine
• Gerbal-Chaloin, Sabine
• Dayeh, Tasnim
• Lassailly, Guillaume
• Mathurin, Philippe
• Staels, Bart
• Auwerx, Johan
• Schürmann, Annette
• Postic, Catherine
• Schafmayer, Clemens
• Hampe, Jochen
• Bonnefond, Amélie
• Pattou, François
• Froguel, Philippe

Titel

Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes

Ist Teil von

• Diabetes (New York, N.Y.), 2018-07, Vol.67 (7), p.1310-1321

Ort / Verlag

American Diabetes Association

Erscheinungsjahr

2018

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• In type 2 diabetes (T2D), hepatic insulin resistance is strongly associated with nonalcoholic fatty liver disease (NAFLD). In this study, we hypothesized that the DNA methylome of livers from patients with T2D compared with livers of individuals with normal plasma glucose levels can unveil some mechanism of hepatic insulin resistance that could link to NAFLD. Using DNA methylome and transcriptome analyses of livers from obese individuals, we found that hypomethylation at a CpG site in PDGFA (encoding platelet-derived growth factor α) and PDGFA overexpression are both associated with increased T2D risk, hyperinsulinemia, increased insulin resistance, and increased steatohepatitis risk. Genetic risk score studies and human cell modeling pointed to a causative effect of high insulin levels on PDGFA CpG site hypomethylation, PDGFA overexpression, and increased PDGF-AA secretion from the liver. We found that PDGF-AA secretion further stimulates its own expression through protein kinase C activity and contributes to insulin resistance through decreased expression of insulin receptor substrate 1 and of insulin receptor. Importantly, hepatocyte insulin sensitivity can be restored by PDGF-AA–blocking antibodies, PDGF receptor inhibitors, and by metformin, opening therapeutic avenues. Therefore, in the liver of obese patients with T2D, the increased PDGF-AA signaling contributes to insulin resistance, opening new therapeutic avenues against T2D and possibly NAFLD.